{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:04:23Z","timestamp":1778929463022,"version":"3.51.4"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"5","content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0019848","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T20:57:09Z","timestamp":1304974629000},"page":"e19848","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Characterization of a Human Antibody Fragment Fab and Its Calcium Phosphate Nanoparticles that Inhibit Rabies Virus Infection with Vaccine"],"prefix":"10.1371","volume":"6","author":[{"given":"Xinjian","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongcan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,5,9]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1348-0421.2005.tb03735.x","article-title":"Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability.","volume":"49","author":"T Ando","year":"2005","journal-title":"Microbiol Immunol"},{"key":"ref2","first-page":"15","article-title":"Prospects for immunization against rabies in developing countries.","author":"FX Meslin","year":"2001"},{"key":"ref3","article-title":"WHO Expert Consultation on Rabies.","year":"2005"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1086\/375605","article-title":"Rabies update for travel medicine advisors.","volume":"37","author":"H Wilde","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref5","first-page":"1","article-title":"WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies","year":"1996"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates.","volume":"25","author":"SE Sloan","year":"2007","journal-title":"Vaccine"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cimid.2007.11.004","article-title":"Ovine anti-rabies antibody production and evaluation.","volume":"32","author":"el-RM Redwan","year":"2009","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2249.2001.01515.x","article-title":"Selection of single chain variable fragments (scFv) against the glycoprotein antigen of the rabies virus from a human synthetic scFv phage display library and their fusion with the Fc region of human IgG1.","volume":"125","author":"K Ray","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.biomaterials.2009.11.093","article-title":"Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.","volume":"31","author":"S Wagner","year":"2010","journal-title":"Biomaterials"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer.","volume":"14","author":"K Cho","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream.","volume":"303","author":"TM Allen","year":"2004","journal-title":"Science"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0168-3659(99)00236-9","article-title":"Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics.","volume":"65","author":"PS Stayton","year":"2000","journal-title":"J Control Release"},{"key":"ref13","first-page":"217","article-title":"GP gene sequencing of three passages of current rabies vaccine strain CTN-1-V in China.","volume":"2006;19","author":"PG Ming","journal-title":"Chin J Biologicals (in Chinese)"},{"key":"ref14","article-title":"Phage display: A laboratory manual. 1rd ed","author":"CarlosF Barbas III","year":"2004"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1016\/j.vaccine.2009.05.055","article-title":"Peptide mimotopes of rabies virus glycoprotein with immunogenic activity.","volume":"27","author":"M Houimel","year":"2009","journal-title":"Vaccine"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel Human Monoclonal Antibody Combination Effectively Neutralizing Natural Rabies Virus Variants and Individual In Vitro Escape Mutants.","volume":"79","author":"AB Bakker","year":"2005","journal-title":"J Virol"},{"key":"ref17","first-page":"191","article-title":"Laboratory methods for rabies diagnosis","author":"H Bourhy","year":"1990"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.vaccine.2006.12.012","article-title":"Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people.","volume":"25","author":"M Feyssaguet","year":"2007","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.med.58.061705.145053","article-title":"A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis.","volume":"58","author":"J de Kruif","year":"2007","journal-title":"Annu Rev Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin.","volume":"193","author":"J Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/375247","article-title":"Development of a cocktail of recombinant- expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies.","volume":"188","author":"M Prosniak","year":"2003","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.micinf.2008.02.008","article-title":"Novel human 3-domain disulfide-stabilized antibody fragment against glycoprotein of rabies virus.","volume":"10","author":"Kun Cai","year":"2008","journal-title":"Microbes and Infection"},{"key":"ref23","article-title":"_ WHO Expert Consultation on Rabies.","year":"2004"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/JVI.64.8.3804-3809.1990","article-title":"Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine.","volume":"64","author":"B Dietzschold","year":"1990","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/JVI.69.3.1444-1451.1995","article-title":"Conzelmann, Mokola virus glycoprotein and chimeric proteins can replace rabies virus glycoprotein in the rescue of infectious defective rabies virus particles.","volume":"69","author":"T Mebatsion","year":"1995","journal-title":"J Virol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0019848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T01:13:32Z","timestamp":1592529212000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0019848"}},"subtitle":[],"editor":[{"given":"Wei-Chun","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,5,9]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0019848","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,9]]}}}